Zenas BioPharma (ZBIO) Earnings Analysis

Zenas BioPharma (ZBIO) next reports earnings on 2026-08-11, consensus EPS -0.89 USD. Last quarter (2026-03-16) it missed with EPS -1.1 USD vs -1.00141 USD est (-9.8%). It has beaten estimates in 1/2 recent quarters (50%). Trailing P/E -3.46.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does ZBIO next report earnings?

Next earnings date2026-08-11
Consensus EPS estimate-0.89 USD
Revenue estimate0.01B

ZBIO earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-16-1.1 USD-1.00141 USD-9.8%Miss
2025-05-15-0.8 USD-1.11 USD+27.9%Beat

Beat rate: 1/2 (50%) over reported quarters with consensus data.

ZBIO valuation and analyst view

Trailing P/E-3.46
Trailing EPS-7.64321 USD
Price / book5.22
Dividend yield0.00%
Market cap1.42B
Analyst consensusBuy (4 buy / 1 hold / 0 sell)
Avg price target22 USD

Related research pages

Frequently asked questions

When is Zenas BioPharma (ZBIO)'s next earnings date?

Zenas BioPharma is next scheduled to report on 2026-08-11, with a consensus EPS estimate of -0.89 USD and revenue estimate of 0.01B.

Did ZBIO beat earnings last quarter?

In its 2026-03-16 report, ZBIO posted EPS of -1.1 USD versus a -1.00141 USD estimate — a miss of 9.8%.

What is ZBIO's earnings track record?

Over the last 2 reported quarters with consensus data, ZBIO beat estimates 1 times (50%).

What is ZBIO's current P/E ratio and EPS?

ZBIO trades at a trailing P/E of -3.46 on trailing EPS of -7.643214747797608 USD.

What do analysts rate ZBIO?

Analyst consensus is "Buy" across 5 ratings (0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 22 USD.